IJE Advance Access originally published online on October 25, 2005
International Journal of Epidemiology 2005 34(6):1329-1339; doi:10.1093/ije/dyi206
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2005
Infectious Diseases |
A mathematical model to estimate global hepatitis B disease burden and vaccination impact
1 Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.
2 National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA.
* Corresponding author. Division of Viral Hepatitis, Mailstop D-66, 1600 Clifton Road, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. E-mail: sgoldstein{at}cdc.gov
Background Limited data are available regarding global hepatitis B virus (HBV)-related morbidity and mortality and potential reduction in disease burden from hepatitis B vaccination.
Methods A model was developed to calculate the age-specific risk of acquiring HBV infection, acute hepatitis B (illness and death), and progression to chronic HBV infection. HBV-related deaths among chronically infected persons were determined from HBV-related cirrhosis and hepatocellular carcinoma (HCC) mortality curves, adjusted for background mortality. The effect of hepatitis B vaccination was calculated from vaccine efficacy and vaccination series coverage, with and without administration of the first dose of vaccine within 24 h of birth (i.e. birth dose) to prevent perinatal HBV infection.
Results For the year 2000, the model estimated 620 000 persons died worldwide from HBV-related causes: 580 000 (94%) from chronic infection-related cirrhosis and HCC and 40 000 (6%) from acute hepatitis B. In the surviving birth cohort for the year 2000, the model estimated that without vaccination, 64.8 million would become HBV-infected and 1.4 million would die from HBV-related disease. Infections acquired during the perinatal period, in early childhood (<5 years old), and 
5 years of age accounted for 21, 48, and 31% of deaths, respectively. Routine infant hepatitis B vaccination, with 90% coverage and the first dose administered at birth would prevent 84% of global HBV-related deaths.
Conclusion Globally, most HBV-related deaths result from the chronic sequelae of infection acquired in the perinatal and early childhood periods. Inclusion of hepatitis B vaccine into national infant immunization programs could prevent >80% of HBV-related deaths.
Keywords Hepatitis B, chronic hepatitis B, chronic liver disease, cirrhosis, hepatocellular carcinoma, hepatitis B vaccine
Accepted 19 September 2005
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. B. Thomas, M. Davila, and J. L. Abbruzzese Stemming the Tide of Hepatitis B Virus-Related Hepatocellular Carcinoma? J. Clin. Oncol., January 10, 2008; 26(2): 172 - 174. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sapru, P. S. Kulkarni, S. Bhave, A. Bavdekar, S. S. Naik, and A. N. Pandit Immunogenicity and Reactogenicity of Two Recombinant Hepatitis B Vaccines in Small Infants: A Randomized, Double-Blind Comparative Study J Trop Pediatr, October 1, 2007; 53(5): 303 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Progress in Hepatitis B Prevention Through Universal Infant Vaccination China, 1997-2006 JAMA, August 1, 2007; 298(5): 506 - 509. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Davaalkham, T. Ojima, S. Wiersma, T. Lkhagvasuren, P. Nymadawa, R. Uehara, M. Watanabe, I. Oki, and Y. Nakamura Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey J Epidemiol Community Health, July 1, 2007; 61(7): 578 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 In brief BMJ, December 17, 2005; 331(7530): 1422 - 1422. [Full Text] [PDF]
|
|